Back to top
more

Kura Oncology (KURA)

(Delayed Data from NSDQ)

$22.17 USD

22.17
582,332

-0.81 (-3.52%)

Updated May 17, 2024 04:00 PM ET

After-Market: $22.20 +0.03 (0.14%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KURA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Kura Oncology, Inc. [KURA]

Reports for Purchase

Showing records 201 - 220 ( 254 total )

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 201

09/16/2019

Daily Note

Pages: 4

KO-539 Hits the Clinic Ready to Make a Splash

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 202

09/03/2019

Company Report

Pages: 4

Positive Ph 2 Data for Tipifarnib in HRAS-Mutant Urothelial Cancer IST Study

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 203

09/03/2019

Daily Note

Pages: 4

Tipifarnib Market Potential Continues to Broaden

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 204

08/02/2019

Company Report

Pages: 7

2Q19 Results; Building the Depth and Breadth Story for Tipifarnib; Adjusting target to $29

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 205

08/02/2019

Company Report

Pages: 7

Q2 Financials; Tipifarnib Potential Continues to Broaden; Pipeline Progresses

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 206

08/02/2019

Daily Note

Pages: 17

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 207

06/18/2019

Industry Report

Pages: 16

HEALTHCARE -EHA Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 208

06/17/2019

Company Report

Pages: 9

EHA Presentations: Positive Ph 2 data for AITL and CXCL12+ Cohorts

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 209

06/17/2019

Company Report

Pages: 9

EHA Presentations: Positive Ph 2 data for AITL and CXCL12+ Cohorts

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 210

06/17/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 211

06/14/2019

Company Report

Pages: 10

Precision Medicine Thesis Takes Big Leap Forward; Looking Ahead to Regulatory Visibility

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 212

05/08/2019

Company Report

Pages: 7

Q1 Financials, PTCL Oral Presentations at EHA and ICML in June

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 213

05/08/2019

Company Report

Pages: 7

Q1 Financials, PTCL Oral Presentations at EHA and ICML in June

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 214

05/08/2019

Company Report

Pages: 7

1Q19 Results; Time for Investors to Get off the Sidelines and Believe in the Targeted Strategy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 215

04/05/2019

Industry Report

Pages: 23

Biotechnology - AACR Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 216

04/03/2019

Daily Note

Pages: 5

Further Delineating Tipifarnib MoA and Encouraging Path Forward; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 217

03/08/2019

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 218

03/08/2019

Company Report

Pages: 7

Q4 Financials; KO-539 into Clinic; Potential Tipi Opportunities Broaden

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 219

03/06/2019

Company Report

Pages: 7

2018 Results; Expect Meaningful Strides in 2019 From the Biomarker-Driven Story of Tipifarnib; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 220

01/22/2019

Company Report

Pages: 11

2019 Outlook Focuses on Breadth of Tipifarnib Opportunities; Independent Data on Two Biomarkers

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party